Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jan G.M. Klijn

Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression as First-Line Chemotherapy in Patients With HER2+ Metastatic Breast Cancer: HERTAX Trial

Clinical Breast Cancer

Cancer Research

Oncology

2011

English

Erratum: Corrigendum: BRCA1 Genomic Deletions Are Major Founder Mutations in Dutch Breast Cancer Patients

Nature Genetics

Genetics

1997

English

Related publications

Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial

Journal of Cellular Physiology

Clinical Biochemistry

Cell Biology

Physiology

2016

English

Capecitabine in Combination With Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: An Observational Study

Pathology and Oncology Research

English

A Randomized Phase III Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-Line Therapy for Patients With Breast Cancer (CBCRT01)

International Journal of Cancer

Cancer Research

Oncology

2017

English

Phase II Randomized Study of Figitumumab Plus Docetaxel and Docetaxel Alone With Crossover for Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research

Cancer Research

Oncology

2014

English

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Clinical Breast Cancer

Cancer Research

Oncology

2014

English

A Phase II Trial of Docetaxel and Erlotinib as First-Line Therapy for Elderly Patients With Androgen-Independent Prostate Cancer

English

Outcome of Combination Chemotherapy With Docetaxel, Estramustine Phosphate, and Carboplatin After Docetaxel and Prednisolone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Journal of Cancer Therapy

2016

English

Phase II Study of Docetaxel and Irinotecan Combination Chemotherapy in Metastatic Gastric Carcinoma

British Journal of Cancer

Cancer Research

Oncology

2006

English

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jan G.M. Klijn

Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression as First-Line Chemotherapy in Patients With HER2+ Metastatic Breast Cancer: HERTAX Trial

Erratum: Corrigendum: BRCA1 Genomic Deletions Are Major Founder Mutations in Dutch Breast Cancer Patients

Related publications

Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial

Capecitabine in Combination With Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: An Observational Study

A Randomized Phase III Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-Line Therapy for Patients With Breast Cancer (CBCRT01)

Phase II Randomized Study of Figitumumab Plus Docetaxel and Docetaxel Alone With Crossover for Metastatic Castration-Resistant Prostate Cancer

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

A Phase II Trial of Docetaxel and Erlotinib as First-Line Therapy for Elderly Patients With Androgen-Independent Prostate Cancer

Outcome of Combination Chemotherapy With Docetaxel, Estramustine Phosphate, and Carboplatin After Docetaxel and Prednisolone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase II Study of Docetaxel and Irinotecan Combination Chemotherapy in Metastatic Gastric Carcinoma

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer